Should dabigatran or vitamin K antagonists be used in prevention of stroke in patients with atrial fibrillation?

被引：1

作者：

Calvo Romero, J. M. ^{[1
]}

机构：

[1] Hosp Ciudad Coria, Med Interna Serv, Coria, Caceres, Spain

来源：

REVISTA CLINICA ESPANOLA | 2011年 / 211卷 / 03期

关键词：

Dabigatran; Direct thrombin inhibitor; Vitamin K antagonist; Atrial fibrillation; INTERNATIONAL NORMALIZED RATIO; DIRECT THROMBIN INHIBITOR; ORAL ANTICOAGULATION; RISK STRATIFICATION; PREDICTING STROKE; GENERAL-PRACTICE; WARFARIN; THERAPY; MANAGEMENT; ETEXILATE;

D O I：

10.1016/j.rce.2010.12.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Patients with atrial fibrillation (AF) at risk of stroke are not always anticoagulated with vitamin K antagonists (VKA) despite lack of contraindication. Dabigatran, an oral direct thrombin inhibitor, is a new option with proven safety and effectiveness in these patients. The advantages of dabigatran are its more predictable response, obviating coagulation monitoring and possible lower frequency of bleedings. Its drawbacks are cost, lack of antidote and long-term data, frequency of dyspepsia and the twice daily dosage. (C) 2011 Elsevier Espana, S.L. All rights reserved.

引用

页码：142 / 146

页数：5

共 50 条

[31] ECONOMIC EVALUATION OF DABIGATRAN FOR STROKE PREVENTION AMONG PATIENTS WITH ATRIAL FIBRILLATION IN THE NETHERLANDS
Le, H. H.
Pechlivanoglou, P.
Engelfriet, P. M.
Postma, M. J.
Redekop, W. K.
VALUE IN HEALTH, 2012, 15 (07) : A370 - A370
[32] Spotlight on Dabigatran Etexilate in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation
Garnock-Jones, Karly P.
DRUGS & AGING, 2011, 28 (05) : 415 - 419
[33] Clopidogrel or apixaban in atrial fibrillation patients unsuitable for vitamin-K antagonists for stroke prevention in atrial fibrillation? Lessons from the recent aspirin-controlled trials
Verheugt, F. W. A.
Jaspersfocks, J.
Brouwer, M. A.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183 : 672 - 672
[34] Clopidogrel or apixaban in atrial fibrillation patients unsuitable for vitamin-K antagonists for stroke prevention in atrial fibrillation? Lessons from the recent aspirin-controlled trials
Verheugt, F. W. A.
Jaspersfocks, J.
Brouwer, M. A.
EUROPEAN HEART JOURNAL, 2011, 32 : 672 - 672
[35] Bleeding risk in patients treated with dabigatran or vitamin K antagonist for atrial fibrillation
Darwiche, W.
Bejan-Angoulvant, T.
Dievart, F.
Babuty, D.
Angoulvant, D.
Fauchier, L.
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 : 54 - 54
[36] A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation
Lok Bin Yap
Beni Isman Rusani
Dhanan Umadevan
Zulkeflee Muhammad
Azlan Hussin
Surinder Kaur
Razali Omar
Journal of Thrombosis and Thrombolysis, 2014, 38 : 39 - 44
[37] A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation
Bin Yap, Lok
Rusani, Beni Isman
Umadevan, Dhanan
Muhammad, Zulkeflee
Hussin, Azlan
Kaur, Surinder
Omar, Razali
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2014, 38 (01) : 39 - 44
[38] Pharmacogenetics of anticoagulants used for stroke prevention in patients with atrial fibrillation
Kampouraki, Emmanouela
Kamali, Farhad
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2019, 15 (06) : 449 - 458
[39] Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: a nationwide retrospective observational study
Lena M. Paschke
Kerstin Klimke
Attila Altiner
Dominik von Stillfried
Maike Schulz
BMC Medicine, 18
[40] Apixaban or Vitamin K Antagonists for Stroke Prevention in Patients With Atrial Fibrillation on Hemodialysis: Results of the Randomized Axadia-AFNET 8 Trial
Reinecke, Holger
Bauersachs, Rupert
Breithardt, Gunter
Engelbertz, Christiane
Gerss, Joachim
Gaerlich, Dennis
Juergensmeyer, Sabine
Wanner, Christoph
Kirchhof, Paulus
CIRCULATION, 2022, 146 (25) : E589 - E590

← 1 2 3 4 5 →